



Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs

April 8, 2019

HAMILTON, Bermuda, April 08, 2019 (GLOBE NEWSWIRE) -- [Kiniksa Pharmaceuticals, Ltd.](http://www.kiniksa.com) (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it will present preclinical data for KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor, at the Keystone Symposia, Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies, in Breckenridge, CO.

Details of the presentation are as follows:

- *KPL-404, a CD40 antagonist, blocked antigen-specific antibody responses in an in vivo NHP model and demonstrated strong PK/PD correlation* (Poster # 2036) by Sujatha Muralidharan¹, Brendan J. Classon¹, Karalyne Crowder², Andrea S.L. Wong², Yoshinobu Yokota², Florence Burleson³, Tracy Garron¹, Moses Njenga¹, John F. Paolini¹ will be presented during Poster Session 2 on Tuesday, April 9th, 2019 at 7:30 p.m. Mountain Time in the Breckenridge Ballroom at the Beaver Run Resort. Kiniksa intends to make the materials available through the Investors and Media section of its website (www.kiniksa.com).

About KPL-404

KPL-404 is an investigational humanized monoclonal antibody that is designed to inhibit the CD40-CD40L interaction, a key T-cell co-stimulatory signal critical for B-cell maturation and immunoglobulin class switching. Dysregulation of the CD40-CD40L pathway has been implicated in multiple autoimmune disease pathologies such as Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren's Syndrome and Grave's Disease.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions. For more information, please visit www.kiniksa.com.

¹Kiniksa Pharmaceuticals Corp., MA, USA; ²Altasciences Preclinical Seattle LLC, WA, USA; ³Burleson Research Technologies Inc, NC, USA

Every Second Counts!TM

Kiniksa Investor and Media Contact

Mark Ragosa
(781) 430-8289
mragosa@kiniksa.com



Source: Kiniksa Pharmaceuticals, Ltd.